Rezolute announced that the FDA recommended a pre-BLA meeting for ersodetug for congenital hyperinsulinism, despite the Phase 3 sunRIZE study not meeting its primary endpoint. This recommendation, based on the FDA's review of continuous glucose monitoring (CGM) data, suggests a potential path to market for the drug, offering a significant positive signal for the company.
Rezolute received a significant positive signal from the FDA, which recommended a pre-BLA meeting for its drug ersodetug for congenital hyperinsulinism. This is notable because the Phase 3 sunRIZE study did not meet its primary endpoint based on finger-stick self-monitored blood glucose (SMBG). However, the FDA's review of continuous glucose monitoring (CGM) data, which showed consistent and clinically relevant improvements, led to this recommendation. This development provides a potential pathway for Rezolute to submit a Biologics License Application (BLA) for ersodetug, which could be a major catalyst for the company. While the FDA explicitly stated this doesn't guarantee approval, the invitation for a pre-BLA meeting is a crucial step forward, especially given the initial trial results. Traders should monitor the upcoming topline results for the upLIFT study in tumor HI, as this will influence Rezolute's overall BLA submission strategy and could further impact the stock.